NASDAQ DE false 0001095981 0001095981 2024-03-12 2024-03-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D)

OF THE SECURITIES EXCHANGE ACT OF 1934

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): March 12, 2024

PLUS THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in its Charter)

DELAWARE |  | 001-34375 |  | 33-0827593
(State or Other Jurisdiction of Incorporation or Organization) |  | (Commission File No.) |  | (I.R.S. Employer Identification No.)

4200 Marathon Blvd., Suite 200, Austin, Texas 78756

(Address of principal executive offices and zip code)

(737) 255-7194

(Registrant’s telephone number, including area code)

(Former name or former address, if changed from last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

Title of each class |  | Trading Symbol (s) |  | Name of each exchange on which registered
Common Stock, par value $0.001 per share |  | PSTV |  | The Nasdaq Capital Market

Item 7.01 | Regulation FD Disclosure.

On March 12, 2024, Marc Hedrick, M.D., President and Chief Executive Officer of Plus Therapeutics, Inc. (the “Company”) presented at a JonesResearch webcast. A recording of the presentation is available under the “For Investors” tab of the Company’s website at www.plustherapeutics.com. The slides accompanying the presentation (the “Presentation Slides”) are being furnished with this Current Report on Form 8-K as Exhibit 99.1 and incorporated herein by reference. The Company is also expected to use the Presentation Slides at upcoming meetings with investors, analysts and others.

The information in this Current Report on Form 8-K, including the exhibits, shall not be deemed “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), as amended, or otherwise subject to the liabilities of such section, and shall not be deemed to be incorporated by reference into the filings of the Company under the Securities Act of 1933, as amended, or the Exchange Act.

Item 9.01 | Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number |  | Description
99.1 |  | Investor Slides dated March 12, 2024
104 |  | Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

|  |  |  | PLUS THERAPEUTICS, INC.
Date: March 13, 2024 |  |  |  | By: |  | /s/ Marc H. Hedrick, M.D.
|  |  |  |  |  | Name: Marc H. Hedrick, M.D.
|  |  |  |  |  | Title: President and Chief Executive Officer